HPLC purity
Reverse-phase HPLC with UV detection; purity target reported per lot with related-substance reporting on request.
Pepti · Catalog · CJC-1295 without DAC (Mod GRF 1-29)
Growth-hormone axis · research-use
CJC-1295 without DAC wholesale & OEM supply.
Lyophilized Modified GRF (1-29) — the no-DAC, shorter-acting CJC-1295 variant — in 2 mg / 5 mg / 10 mg vials for research labs, med spas and private-label brands, with COA + HPLC + MS on every lot.
CJC-1295 without DHPLC ≥ 98%MS confirmed2mg
Vial illustrations reflect supplied lyophilized format. Distribution scope and destination market confirmed before invoicing.
| Compound | CJC-1295 without DAC (Mod GRF 1-29) |
|---|---|
| CAS number | 446036-97-1 |
| Class | Growth-hormone axis & repair |
| Molecular formula | C152H252N44O42 |
| Molecular weight | 3367.9 g/mol |
| Sequence | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 |
| Form | Lyophilized powder, sterile glass vial |
| Purity target | ≥ 98% by HPLC |
| Vial formats | 2mg / 5mg / 10mg |
| Documentation | COA + HPLC + MS, batch lot file where available |
| Distribution scope | Research use, worldwide |
| Storage | Lyophilized powder: store at 2–8 °C protected from light for short-term handling; −20 °C for long-term storage. Ships ambient-stable for transit; keep reconstituted vials refrigerated and protected from light. |
MOQ & lead time
| Tier | Quantity | Lead time |
|---|---|---|
| Sample lot | From 50 vials | 3–7 days |
| Production lot | 200–1,000 vials | 10–14 days |
| OEM repeat | 1,000+ vials | 14–18 days, scheduled |
CJC-1295 without DAC (Modified GRF 1-29) is a tetrasubstituted 29-amino-acid GHRH analog supplied as a research-use lyophilized peptide, distinct from the longer-acting DAC variant.
Documentation
Batch documentation support for CJC-1295 without DAC (Mod GRF 1-29) lots.
COA / HPLC / MS document support where available. Distribution scope confirmed before invoicing.
MS identity
Mass spectrometry identity confirmation against the CJC-1295 without DAC (Mod GRF 1-29) reference profile.
Lot traceability
Compound prefix and lot serial printed on the vial label and repeated in the document pack and carton.
FAQ
CJC-1295 without DAC (Mod GRF 1-29) — frequently asked by B2B buyers.
How is CJC-1295 without DAC different from the DAC version?
The no-DAC form is Modified GRF (1-29) — the same tetrasubstituted GHRH sequence but without the albumin-binding Drug Affinity Complex, so it has a lower molecular weight (approx. 3367.9 g/mol vs approx. 3647 g/mol for the DAC form) and a shorter circulating half-life. Buyers specify which variant their protocol requires; we supply both as separate SKUs and can quote them on one invoice.
What documentation ships with each lot?
Every lot ships with a COA plus a reverse-phase HPLC purity chromatogram and mass-spectrometry identity confirmation against the Mod GRF (1-29) reference profile, with lot-code traceability. The current-batch COA can be shared for review before payment.
What vial sizes and MOQ do you offer?
Standard formats are 2 mg, 5 mg and 10 mg lyophilized vials. MOQ is 50 vials for sample lots, with tiered pricing on 200+ vial production runs and scheduled OEM repeats above 1,000 vials. Custom fills, labeling and private-label packaging are available as services.
Is CJC-1295 without DAC often sourced alongside other peptides?
In research protocols it is frequently paired with a GHRP such as ipamorelin or GHRP-2 for complementary GHRH + GHRP coverage. We supply each as separate lyophilized vials and can quote them together. It is also commonly compared with the DAC variant and with sermorelin.
What purity and grade do you supply, and for what use?
Target purity is at least 99% by HPLC (area %), confirmed per lot by HPLC and MS. Material is supplied strictly for laboratory research and manufacturing use, not for human or clinical use; buyer qualification and destination country are confirmed before invoicing.
Related compounds